Core Insights - Clearmind Medicine Inc. has completed the treatment of the first patient cohort in its Phase I/IIa clinical trial for CMND-100, targeting Alcohol Use Disorder (AUD) [1][5] - The global alcohol-dependency treatment market is projected to grow from approximately $13.2 billion in 2024 to about $20 billion by 2032, indicating a significant unmet need for effective treatments [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [7] Clinical Trial Details - The Phase I/IIa trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - The trial includes participants from leading research centers, with six patients successfully enrolled and treated, including two from Johns Hopkins University and four from Yale School of Medicine [2][3]

Core Points - Clearmind Medicine Inc. received a Notification Letter from Nasdaq indicating non-compliance with Listing Rule 5550(b)(1) due to insufficient stockholders' equity [1][2] - The company's stockholders' equity was reported at $1,065,668, below the required minimum of $2,500,000 [2] - The Notification Letter does not immediately affect the company's listing status, and shares continue to trade under the symbol "CMND" [3] Compliance Plan - Clearmind has 45 days to submit a plan to regain compliance, with a deadline of December 18, 2025 [3] - If the plan is accepted, Nasdaq may grant an extension of up to 180 days to demonstrate compliance [3] - The company is exploring various options to regain compliance and intends to submit the plan as soon as possible [4] Financial Strategies - The company entered into securities purchase agreements to issue convertible promissory notes totaling up to $10,000,000 [5] - As of late October 2025, $1,045,062 of these notes were converted into 885,000 common shares [5] - The company expects that further conversions of the notes will help meet Nasdaq's stockholders' equity requirement [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues [6] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [7]

Core Insights - Clearmind Medicine Inc. has filed a patent application in South Korea for its proprietary compound MEAI, aimed at treating depression, thereby enhancing its global intellectual property protection [1][2][4] - MEAI is a non-hallucinogenic neuroplastogen that modulates serotonin pathways and promotes neuroplasticity, offering a new therapeutic approach for major depressive disorder, which affects over 280 million people globally [3][4] - The company has a robust intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and expand its IP protection [5][6] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, including depression and alcohol use disorder [1][5] - The company is preparing for the next stages of clinical development and commercialization of its non-hallucinogenic therapies, aiming to bring these treatments to patients worldwide [5][6]

Core Insights - Clearmind Medicine Inc. has announced a U.S. patent application for its non-hallucinogenic compound MEAI, aimed at treating cocaine addiction, enhancing its intellectual property portfolio [1][2][4] - Cocaine use disorder is a significant global health issue with no FDA-approved treatments, presenting a market opportunity projected to grow from $1.36 billion in 2025 to $2.03 billion by 2032 [2] - MEAI is designed to modulate serotonin and dopamine pathways, potentially offering a safer alternative to existing behavioral interventions for addiction [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health problems, including addiction [1][4] - The company currently holds nineteen patent families with 31 granted patents and plans to pursue additional patents to strengthen its intellectual property [5] Market Context - The global market for cocaine addiction treatment is experiencing urgent demand for new solutions, highlighting the potential impact of Clearmind's developments in this area [2][3]

Core Insights - Clearmind Medicine Inc. is advancing its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the last patient in the first cohort having received treatment [1][5] - The global alcohol-dependency treatment market is projected to grow from approximately $13.2 billion in 2024 to about $20 billion by 2032, indicating a significant unmet need for effective treatments [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [6] - The company holds a portfolio of nineteen patent families with 31 granted patents and aims to expand its intellectual property [7] Clinical Trial Details - The Phase I/IIa trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - The trial includes six patients treated at prestigious institutions like Johns Hopkins University and Yale School of Medicine, with additional sites activated in Israel [2][3] Market Opportunity - The urgent need for more effective AUD treatments is highlighted by the projected growth of the treatment market, emphasizing the commercial potential for new therapeutic approaches [4]

Core Insights - Clearmind Medicine Inc. is participating in a webinar focused on women in psychedelic leadership, highlighting its commitment to advancing psychedelic medicine [1][2] - The CEO, Dr. Adi Zuloff-Shani, will share insights on the company's strategic direction and the broader psychedelic landscape [2][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder, cocaine addiction, and obesity [1][4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as needed [5] Event Details - The webinar titled "Women in Psychedelic Leadership: Driving Innovation & Governance" is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online [1][2][3] - Registration for the event is available through Eventbrite, inviting investors, researchers, and stakeholders to participate [3]

Core Insights - Clearmind Medicine Inc. has appointed Mary-Elizabeth Gifford as Chief of Global Impact to enhance US partnerships and regulatory advocacy in the psychedelic medicine sector [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogens-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of 19 patent families with 31 granted patents and aims to expand this portfolio opportunistically [5] Leadership and Expertise - Mary-Elizabeth Gifford previously served as Chief of Global Impact at Psyence BioMed and has extensive experience in psychedelic policies and regulatory landscapes [2][3] - Gifford has been recognized as a significant figure in the psychedelic industry, being named a "Psychedelic Titan" and described as "the most quietly influential woman working in psychedelics today" [3] Strategic Initiatives - Gifford's role will focus on bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines [1][3] - Clearmind is conducting clinical trials at prestigious institutions such as Yale School of Medicine and Johns Hopkins University, aiming to set industry standards for scientific rigor [3]

Core Insights - Clearmind Medicine Inc. has completed the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial for CMND-100, a proprietary oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Clinical Trial Details - The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - Six patients have been successfully enrolled in the trial, with two at Johns Hopkins University and four at Yale School of Medicine [2] - The trial is registered on ClinicalTrials.gov under the identifier NCT05913752 [4] Management Commentary - The CEO of Clearmind expressed enthusiasm about reaching a key milestone in the trial and highlighted the efficient enrollment process, which was completed within an excellent timeline [4]

Core Insights - Clearmind Medicine Inc. has announced the publication of a U.S. patent application for a combination therapy involving 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, targeting binge behavior disorders [1][2] - The therapy aims to address various binge behaviors, including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct, by leveraging MEAI's neuroplastic properties [2][3] - The company has filed a total of 13 patents related to its collaboration with SciSparc Ltd., focusing on conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [5] - The company's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Strategic Goals - The CEO of Clearmind emphasized the company's mission to pioneer safe and effective treatments for binge behaviors, aiming to meet unmet needs in addiction medicine [4][8] - The combination of MEAI and PEA is positioned as a potentially safer and more effective treatment option compared to existing therapies [2][4]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a U.S. patent application for a combination therapy targeting binge behavior disorders [1][2] - The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, such as Palmitoylethanolamide (PEA), which may provide a new approach to treating various behavioral addictions [2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs based on THC and non-psychoactive cannabidiol [4] - The company is currently working on treatments for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4] Collaboration Details - The collaboration with Clearmind focuses on the potential of PEA-MEAI combinations to address conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data suggests that this combination therapy may effectively mitigate binge episodes while preserving natural reward pathways [3] Clearmind Medicine Inc. Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing novel psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a diverse intellectual property portfolio consisting of 19 patent families and 31 granted patents [5]